Sutro Biopharma regains Nasdaq minimum bid price compliance after prior deficiency

SUTRO BIOPHARMA, INC.

Received Nasdaq notice on Dec 17, 2025 confirming compliance with Listing Rule 5450(a)(1) after 10 consecutive business days with closing bid at or above $1.00.
Non-compliance was initially disclosed on June 20, 2025 when bid price fell below $1.00 for 30 consecutive business days.
Listing matter is now closed; company meets all other Nasdaq Global Market continued listing criteria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.